The iDose TR slow-eluting travoprost intraocular implant (Glaukos) controlled IOP in more subjects than timolol 0.5% at 3 years. Investigators evaluated the percentage of subjects in the implant arm vs those assigned topical drops who were controlled on the same (or fewer) medications at 3 years as at screening, according to Joshua Kim, MD, speaking at the 2023 annual meeting of the American Academy of Ophthalmology.

Participants were on 0 to 3 IOP-lowering medications at screening with nonmedicated mean IOP ≥21 mmHg to ≤36 mmHg. Safety and IOP were assessed, and medication was added if IOP was ≥30 mmHg at day 3 or >18 mmHg at week 4 or later. A total of 54 slow-eluting, 51 fast-eluting, and 49 timolol patients were randomized. At 3 years, 69% of slow-eluting implant patients vs 45% of timolol patients were well controlled on the same (or fewer) topical medications vs screening.